Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Haptic And Exoskeleton Devices For Neurorehabilitation Of Upper Limb Paralysis: A State Of Art And A Night Landing Task, Samantha Renee Wagner
Haptic And Exoskeleton Devices For Neurorehabilitation Of Upper Limb Paralysis: A State Of Art And A Night Landing Task, Samantha Renee Wagner
All NMU Master's Theses
Rehabilitation is an important training phase for those suffering from upper limb paralysis as a result of brain injury. When successfully completed, the re-trained limb should be able to successfully complete daily life activities. An alternative to traditional therapy is the usage of effective rehabilitation by using haptic devices in a virtual environment. The type of haptic device and task are crucial for the success of the therapy training sessions. After presenting a state-of-art literature review of several haptic devices that has been used in research and clinical facilities, we thought to use the black hole illusion (BHI), a night …
An Introduction To Drugs And The Neuroscience Of Behavior, Adam J. Prus
An Introduction To Drugs And The Neuroscience Of Behavior, Adam J. Prus
Books
This up-to-date text provides an introductory overview of the nervous system actions and behavioral effects of the major classes of psychoactive drugs, using pedagogy unique among pharmacology texts to make the topic approachable.
The Quetiapine Active Metabolite N-Desalkylquetiapine And The Neurotensin Nts1 Receptor Agonist Pd149163 Exhibit Antidepressant-Like Effects On Operant Responding In Male Rats, Todd M. Hillhouse, Zachary Shankland, Katelin S. Matazel, Ashley Keiser, Adam J. Prus
The Quetiapine Active Metabolite N-Desalkylquetiapine And The Neurotensin Nts1 Receptor Agonist Pd149163 Exhibit Antidepressant-Like Effects On Operant Responding In Male Rats, Todd M. Hillhouse, Zachary Shankland, Katelin S. Matazel, Ashley Keiser, Adam J. Prus
Journal Articles
Major depressive disorder (MDD) is the most common mood disorder in the United States and European Union; however, the limitations of clinically available antidepressant drugs have led researchers to pursue novel pharmacological treatments. Clinical studies have reported that monotherapy with the atypical antipsychotic drug quetiapine produces a rapid reduction in depressive symptoms that are apparent following one week of quetiapine treatment, and it is possible that the active metabolite N-Desalkylquetiapine, which structurally resembles an antidepressant drug, produces antidepressant effects. Neuropharmacological evaluations of the neurotensin NTS1 receptor agonist PD149163 are suggestive of antidepressant efficacy, but the effects of a NTS …